Definium Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $117.7M | $65.3M | $52.1M | $36.2M | $34.8M |
| Operating expenses | $166.3M | $103.9M | $93.9M | $66.3M | $93.9M |
| Operating income | -$166.3M | -$103.9M | -$93.9M | -$66.3M | -$93.9M |
| Interest expense | $5.5M | $2.3M | $920,000 | — | — |
| Pretax income | -$183.8M | -$108.7M | -$95.7M | -$56.8M | -$94.2M |
| Income tax expense | $0 | — | — | — | -$1.2M |
| Net income | -$183.8M | -$108.7M | -$95.7M | -$56.8M | -$93.0M |
| Balance Sheet | |||||
| Cash and equivalents | $257.8M | $273.7M | $99.7M | $142.1M | $133.5M |
| Current assets | $419.3M | $281.6M | $103.9M | $146.1M | $137.2M |
| Total assets | $440.1M | $302.2M | $124.5M | $170.0M | $164.0M |
| Current liabilities | $66.7M | $38.8M | $32.2M | $17.9M | $10.4M |
| Total liabilities | $107.8M | $60.7M | $46.4M | $19.1M | $12.3M |
| Total debt | $41.0M | $22.0M | $15.0M | — | — |
| Stockholders' equity | $332.3M | $241.4M | $78.1M | $150.9M | $151.7M |
| Cash Flow Statement | |||||
| Cash from operations | -$131.6M | -$79.1M | -$64.4M | -$50.1M | -$45.8M |
| Stock-based compensation | $20.1M | $16.9M | $15.2M | $13.7M | $42.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 109.1M · Free float 97.6%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.